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In this supplementary text, we provide confirmation of our findings in ISAR Risk by testing the 
prognostic value of SAF in three independent post-infarction populations including a total of 2,564 
patients: 
 
1.) St. George’s Hospital Medical School (SGHMS) Post-infarction Survey  
2.) Holter sub-study of the European Myocardial Infarction Amiodarone Trial (EMIAT) 
a. Placebo arm 
b. Amiodarone arm 
3.) Multiple Risk Factor Analysis Trial (MRFAT)  
 
 
Study characteristics 
The study characteristics of the different populations have been described elsewhere (1-4). Table S1 
provides a brief summary of the study characteristics. 
 
Results 
During follow-up of 2 years (EMIAT, MRFAT) and 3 years (SGHMS), respectively, 82/679 (12.1%), 
87/633 (13.7%), 88/625 (14.1%) and 34/597 (5.7%) of the patients died in the SGHMS Post-infarction 
survey, the placebo- and amiodarone arm of EMIAT, and MRFAT.  
 
Risk stratification by LVEF  
In the SGHMS post-infarction survey and in MRFAT (i.e. populations without restriction of LVEF), 
LVEF ≤30% identified only a minority of patients who died during follow up (SGHM 28/82=34%; 
MRFAT 8/34=24%). In the placebo- and amiodarone-arm of EMIAT (LVEF restricted to ≤ 40%), 65% 
(57/87) and 61% (54/88) of deaths occurred in patients with LVEF ≤30%, respectively. Cumulative 
mortality rates of patients with LVEF ≤30% vs. patients with LVEF >30% are shown in panels A, D, G 
and J of Figure S1 for the different populations. See also tables S2-S4 for details. 
 
Risk stratification by SAF in patients with LVEF >30% 
In all populations, SAF was a highly significant predictor of death in the subgroups of patients with 
preserved LVEF (>30%). In the SGHMS Post-infarction survey, SAF identified 29 patients with LVEF 
>30% , out of whom 11 died during follow-up. In the placebo- and amiodarone arm of EMIAT, SAF 
identified 27 and 34 patients with LVEF >30%, out of whom 6 and 11 patients died during follow-up. In 
MRFAT, SAF identified 109 patients with LVEF >30% , out of whom 15 died during follow-up. The 
mortality rates of patients with preserved LVEF (>30%) but positive SAF findings are shown in the 
right column of Figure S1 (Panel C, F, I and L). Their mortality risk was not statistically different from 
that of patients with impaired LVEF (≤30%).    
 
Risk stratification by SAF in the total populations 
In addition to our primary goal of testing the prognostic power of SAF in the so-called low-risk group of 
patients with LVEF >30%, we tested the prognostic power of SAF in the total populations. The 
mortality rates of patients with and without positive SAF findings are shown in the middle column of 
Figure S1 (panels B, E, H and K). In the SGHMS Post-infarction survey, SAF identified 46 patients, out 
of whom 18 patients died. In the placebo- and amiodarone arm of EMIAT, SAF identified 76 and 91 
patients, out of whom 27 patients died, respectively. In MRFAT, SAF identified 134 patients, out of 
whom 19 patients died.  
 
Combination of LVEF ≤30% and SAF for prediction of death 
As shown in the right columns of tables S2-4, combinations of LVEF ≤30% and SAF lead to a 
significant increase of sensitivity in all populations while the positive predictive accuracies were 
preserved. Note that the increase of sensitivity in EMIAT is lower because of the restriction to patients 
with LVEF ≤40% and consequently higher incidence of patients with LVEF ≤30%.  
 
Conclusion 
Post-hoc analyses of the SGHM Post-infarction survey, the placebo- and amiodarone-arm of EMIAT 
and MRFAT clearly confirmed the principal findings of ISAR Risk. Despite significant differences in 
study characteristics (Table S1), SAF was a strong predictor of death in all populations. This was not 
only true for the total populations, but in particular also in the subgroups of patients with preserved 
LVEF (>30%) – i.e. patient groups not covered by present ICD guidelines. In all populations, SAF was 
capable of identifying a high risk group of patients with preserved LVEF, whose prognosis was as 
worse as of patients with reduced LVEF.  
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Figure legend 
Figure S1: Cumulative mortality curves for patients of the St.George’s Medical School (SGHMS) 
Post-infarction Survey, the Holter sub-study of the European Myocardial Infarction Amiodarone Trial 
(EMIAT) and the Multiple Risk Factor Analysis Trial (MRFAT) stratified by left ventricular ejection 
fraction (LVEF; left panels) and stratified by presence of severe autonomic failure (SAF; middle 
panels). Right panels show cumulative mortality curves for patients with LVEF >30% also stratified by 
presence of SAF. 
Tables (supplementary material) 
 
Table S1  Study characteristics  
  SGHMS EMIAT (Holter 
substudy) 
MRFAT 
N 679 1,258  
(625 Plac./ 633 
Amiod.) 
597 
Start of enrollment 1984 1990 1996 
Inclusion criteria Acute MI 
Age ≤75 years 
Sinus rhythm 
Recent MI 
Age ≤75 years 
Sinus rhythm 
LVEF ≤ 40% 
Acute MI 
Age ≤75 years 
Sinus rhythm 
Holter recordings day 7 after index MI Pre-randomization day 7 after index MI 
Follow-up Restricted to 3 years 21 months (median) Restricted to 2 years 
Primary endpoint Death of any cause Death of any cause Death of any cause 
PCI 0% 0% 24% 
Lysis 59% 59% / 56% 41% 
Betablockers 52% 44% / 45% 97% 
MI myocardial infarction 
 
Table S2: SGHMS Post-infarction survey: Mortality rates, sensitivities and specificities for prediction 
of all cause mortality by high-risk groups 
 
 
LV
EF
 
≤
 
30
%
 
SA
F 
SA
F 
(in
 
LV
EF
 
>
30
%
) 
 
 
LV
EF
 
≤
 
30
%
 
or
 
 
LV
EF
 
>
30
%
 
an
d 
SA
F 
Total count 105 46 29 134 
Prediction of all-cause mortality at 3 years 
All cause deaths 28 18 11 39 
Positive predictive 
accuracy (%) 26.7 39.1 37.9 29.1 
Negative predictive 
accuracy (%) 90.6 89.9 89.1 92.1 
Sensitivity (%) 34.1 22.0 13.4 47.6 
Specificity (%) 87.1 95.3 97.0 84.1 
 
LVEF left ventricular ejection fraction; SAF severe autonomic failure; SGHMS St.George’s Hospital 
Medical School 
 
Table S3: Placebo- and amiodarone arm of EMIAT: Mortality rates, sensitivities and specificities for 
prediction of all cause mortality by high-risk groups 
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Placebo Arm (n = 633) 
Total count 296 76 27 324 
Prediction of all-cause mortality at 2 years 
All cause deaths 57 27 6 63 
Positive predictive 
accuracy (%) 19.3 35.5 22.2 19.4 
Negative predictive 
accuracy (%) 90.4 88.6 91.9 91.9 
Sensitivity (%) 65.5 31.0 6.9 72.4 
Specificity (%) 56.2 91.0 96.2 52.2 
Amiodarone Arm (n = 625) 
Total count 300 91 34 334 
Prediction of all-cause mortality at 2 years 
All cause deaths 54 27 11 65 
Positive predictive 
accuracy (%) 18.0 29.7 32.4 19.5 
Negative predictive 
accuracy (%) 87.6 85.6 89.6 89.6 
Sensitivity (%) 62.1 31.0 12.6 74.7 
Specificity (%) 54.9 88.3 95.8 50.7 
 
LVEF left ventricular ejection fraction; SAF severe autonomic failure; EMIAT European Myocardial 
Infarction Amiodarone Trial 
 
Table S4: MRFAT: Mortality rates, sensitivities and specificities for prediction of all cause mortality 
by high-risk groups 
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Total count 58 134 109 167 
Prediction of all-cause mortality at 2 years 
All cause deaths 8 19 15 23 
Positive predictive 
accuracy (%) 13.8 14.2 13.8 13.8 
Negative predictive 
accuracy (%) 95.2 95.9 97.0 97.4 
Sensitivity (%) 23.5 55.9 57.7 67.6 
Specificity (%) 91.1 79.6 81.7 74.4 
 
LVEF left ventricular ejection fraction; SAF severe autonomic failure; MRFAT Multiple Risk Factor 
Analysis  
 
 
 
 
